Ashwini Rajasekaran

About

Dr. Ashwini Rajasekaran is the founder of BioSignatures Tech, leading innovation in neurogenomics and multi-omic biomarker discovery. With a Ph.D. from NIMHANS and Post-doctoral research experience at UBC, St.Paul’s Hospital and MITACS Accelerate Industrial fellowship at Universite de Sherbrooke, her work spans schizophrenia, asthma, transplant diagnostics, and mRNA vaccine development.

Driven by personal experience with delayed diagnosis, Ashwini aims to bridge omics with healthcare outcomes guided by scientific rigor, strategic clarity, and a commitment to equity in precision medicine.

Employment

• University of British Columbia
• BioSignatures Tech Founder

Education

• National Institute of Mental Health and Neurosciences PhD

Projects & Funding

• mRNA Stabilization for vaccine development: Implications for Autoimmune diseases Mitacs
• Genetic determinants of Schizophrenia DST
• Multi-Omic Biomarker discovery for neurodegeneration IISc

Publications (22)

• Circulating Metabolites for Non-Invasive Detection of Acute Cellular Rejection After Heart Transplantation
  The Journal of Heart and Lung Transplantation 2025
  +Save
• A convenient analytic method for gel quantification using ImageJ paired with Python or R
  PloS one 2024
  +Save
• F76. INTERLEUKIN-6 GENE EXPRESSION IN UNAFFECTED FIRST-DEGREE RELATIVES OF SCHIZOPHRENIA: A POTENTIAL ENDOPHENOTYPE?
  European Neuropsychopharmacology 2024
  +Save
• Genomics and gene-based personalized nutrition
  Nutritional health: Strategies for disease prevention 2023
  +Save
• Dendritic cells and their immunotherapeutic potential for treating type 1 diabetes
  International journal of molecular sciences 2022
  +Save
• Cholinergic synapse pathway gene polymorphisms associated with late-phase responses in allergic rhinitis
  Frontiers in Allergy 2021
  +Save
• Impact of NRG1 HapICE gene variants on digit ratio and dermatoglyphic measures in schizophrenia
  Asian Journal of Psychiatry 2020
  +Save
• Leukocyte mitochondrial DNA copy number in schizophrenia
  Asian journal of psychiatry 2020
  +Save
• Cholinergic synapse pathway gene polymorphisms associated with allergen-induced late asthmatic responses
  ERJ open research 2019
  +Save
• CHRFAM7A gene expression in schizophrenia: clinical correlates and the effect of antipsychotic treatment
  Journal of Neural Transmission 2018
  +Save
• Influence of correlation between HLA-G polymorphism and Interleukin-6 (IL6) gene expression on the risk of schizophrenia
  Cytokine 2018
  +Save
• Leukocyte Mitochondrial DNA Copy Number in Schizophrenia
  BIOLOGICAL PSYCHIATRY 2018
  +Save
• Telomere length and its association with hippocampal gray matter volume in antipsychotic-näıve/free schizophrenia patients
  Psychiatry Research: Neuroimaging 2018
  +Save
• Functional interactions of IL6 and CHRFAM7A genes in schizophrenia pathogenesis
  EUROPEAN JOURNAL OF IMMUNOLOGY 2016
  +Save
• TH17 PATHWAY RELATED CYTOKINE GENE POLYMORPHISMS IN GUILLAIN-BARRE SYNDROME
  JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 2016
  +Save
• The impact of HLA-G 3′ UTR variants and sHLA-G on risk and clinical correlates of schizophrenia
  Human Immunology 2016
  +Save
• The impact of IL10 polymorphisms and sHLA-G levels on the risk of schizophrenia
  Asian Journal of Psychiatry 2016
  +Save
• Transcranial direct current stimulation and neuroplasticity genes: implications for psychiatric disorders
  Acta neuropsychiatrica 2016
  +Save
• Mitochondrial dysfunction in schizophrenia: pathways, mechanisms and implications
  Neuroscience & Biobehavioral Reviews 2015
  +Save
• Soluble human leukocyte antigen (sHLA)-G levels may predict early onset of schizophrenia in male patients
  Tissue Antigens 2015
  +Save